Hyaluronic Acid & Hyaluronidase

Hyaluronic Acid (HA), a key component of the extracellular matrix, is a natural glycosaminoglycan with unique water-retaining properties and viscoelasticity. It plays a crucial role in maintaining the structure and function of tissues.

Hyaluronidase (HAase) is a family of enzymes that specifically degrades HA. By hydrolyzing HA molecules, it reduces tissue viscosity and barrier function, thereby reversibly enhancing tissue permeability. This type of enzyme is widely present in nature, and its biological activity holds significant application value in fields such as drug delivery and tissue engineering. Currently, recombinant human hyaluronidases (e.g., rHuPH20) have become the first choice for clinical and scientific research applications due to their high purity and low immunogenicity.

Recombinant Human Hyaluronidase: Ushering in a New Era of Subcutaneous Delivery of Biologics

By specifically degrading the hyaluronic acid matrix in tissues, recombinant human hyaluronidase significantly improves the subcutaneous penetration efficiency of drugs. This mechanism is crucial for solving the delivery challenges of large-molecule biologics (especially monoclonal antibodies) and high-concentration formulations.

Traditionally, large-molecule antibody drugs are limited by their large molecular weight and high viscosity, making them difficult to deliver effectively via subcutaneous injection. They usually rely on time-consuming intravenous infusion. Although high-concentration formulations can reduce the injection volume, their viscosity increases further, which exacerbates the difficulty of subcutaneous injection and patient discomfort. The application of recombinant human hyaluronidase has broken this bottleneck. Currently, a number of recombinant human hyaluronidases and related formulations have been approved for marketing worldwide, including:

· Recombinant human hyaluronidase rHuPH20 from Halozyme Therapeutics;

· Hyqvia from Takeda Pharmaceutical Company (containing 10% active immunoglobulin and recombinant human hyaluronidase);

· Darazalex Faspro (subcutaneous injection of daratumumab [CD38]) from Johnson & Johnson;

· Rituxan Hycela (rituximab) and Herceptin Hylecta (trastuzumab) from Roche.

Overview of Clinical Development Programs for Recombinant Human Hyaluronidase

As of June 2025, the recombinant human hyaluronidase technology platform has been expanded to more than 80 clinical development programs, covering the entire stage from early-phase trials to new drug application (NDA). Among these, approximately 70% are in Phase I/II, 20% have entered Phase III or the marketing stage, and the remaining 10% are already marketed products.

In the future, with the continuous breakthroughs of Chinese enterprises in localized R&D and the collaborative innovation with international high-volume injection technologies, the market prospect of recombinant human hyaluronidase will be even broader. The recombinant human hyaluronidase developed by ImmuneOnco has established a significant differentiated advantage through its high-expression CHO cell platform. It has currently reached a cooperation agreement with Yangtze River Pharmaceutical Group, and is expected to become a key breakthrough in the industrialization of domestic recombinant human hyaluronidase.

XMJ × ImmuneOnco: Safeguarding Your Research

XMJ, in collaboration with ImmuneOnco, provides reliable supply of recombinant human hyaluronidase. Developed in accordance with the standards for injectable pharmaceutical excipients, this enzyme features ultra-high purity (SEC/RPC ≥ 95%) and excellent enzymatic activity. It has also completed the excipient registration with the Center for Drug Evaluation (CDE) of China (Registration No.: F20250000188), providing a safe and compliant delivery solution for your antibody drugs and high-concentration formulations.

Product Ordering Information

Apply for a Trial Immediately

Trials of ImmuneOnco’s recombinant human hyaluronidase are now open for application! To secure your free 1ml trial sample, please follow XMJ’s official WeChat account immediately, send the keyword "IMM67", and fill out the questionnaire. Samples are available in limited quantities, and will be distributed on a first-come, first-served basis.

XMJ has always adhered to a professional and rigorous attitude to provide customers with high-quality products and services. If you are interested in the above-mentioned product, please feel free to call the customer service hotline of Beijing XMJ at 400-050-4006 or visit the website www.emergexcelerate.com to learn more product information.

Profile of ImmuneOnco

ImmuneOnco Biopharmaceutical Technology (Shanghai) Co., Ltd. was founded in June 2015. As a research-oriented biotechnology company, it is committed to the development of cancer immunotherapies and ranks among the few biotech companies worldwide capable of systematically leveraging both innate and adaptive immunity.

ImmuneOnco has been honored with multiple awards and recognitions, including:

· "The 2nd Biotech Innovation Top 50 Enterprises List"

· "Drug Innovation for Public Welfare Award"

· "2021 Top 100 Seed Enterprises in China’s Pharmaceutical Innovation"

· "Top 20 Innovation and Entrepreneurship Enterprises in Pudong New Area (2020)"

· "High-Tech Enterprise Certificate"

· "2019 Top 50 Most Innovative Enterprises in China’s Biopharmaceutical Industry"

· "Zhangjiang Venture Capital Top 100 Enterprises Honorary Title"